The FDA has approved aclidinium bromide (Tudorza Pressair – Forest), an orally-inhaled long-acting anticholinergic, for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

MAINTENANCE TREATMENT OF COPD — In patients with moderate to severe disease, regular treatment with a long-acting bronchodilator can improve lung function, relieve symptoms, decrease the frequency of exacerbations, and improve quality of life. The addition of an inhaled corticosteroid is recommended for patients with severe disease who experience frequent exacerbations.1

CLINICAL STUDIES — Two randomized, double-blind trials in 375 and 542 patients, all with moderate to severe COPD (baseline mean forced expiratory volume in 1 second [FEV₁] 1.33-1.51 L), found that aclidinium 400 mcg inhaled twice ... more      

Would you like to read the rest of this article?  Gain access below.